How RioGin solves the peptide half-life problem...
RioGin's technology is the solution to the two most pressing problems associated with the use of therapeutic peptides – rapid kidney filtration (resulting in the need for frequent injections) and the side effects caused by the high concentration of active peptide drug in the bloodstream. We offer simultaneous control of both peptide half-life and effective concentration with a dose formulation in volumes of less than 20 microliters enabling once-a-week self-administration using nearly painless micro needle injections.
Serum proteins such as hSA (human serum albumin) are abundant and long-lived in plasma, and transport a wide array of molecules (fatty acids, metabolites, and drugs) through the body. A molecule carried by hSA will be refractory to kidney filtration resulting in an increase in the time it spends in the body. RioGin has developed tags that can be added onto peptide drugs to allow them to reversibly bind to hSA. The new entity, a tagged peptide, is more refractory to renal clearance, requiring less frequent administration and smaller doses to induce the pharmacological response.
However, simply increasing the half-life of peptide therapeutics through a single bond with hSA is not a complete solution. The circulating drug concentration must also be stabilized at a level that does not cause adverse side effects.
In addition to increasing the half-life, RioGin has the unique ability to control the concentration of active peptide drug in the body. By adding a second tag for hSA on the peptide a portion of the peptide drug will be inactive and is essentially stored in circulation without being eliminated. By setting the equilibrium concentration with a controlled ratio of active to inactive peptide, RioGin can eliminate the side effects and reactions that occur when the peptide concentration is high.